metyrapone has been researched along with Pituitary ACTH Hypersecretion in 22 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
Pituitary ACTH Hypersecretion: A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A diagnosis of preclinical Cushing's disease was made, and she was treated with 11-hydroxylase inhibitor metyrapone." | 5.34 | Preclinical Cushing's disease characterized by massive adrenal hyperplasia and hormonal changes after three years of metyrapone therapy. ( Nomura, K; Ohmori, K; Ohmori, N; Takano, K, 2007) |
| " This review will rather focus specifically on adverse events associated with these drugs (ketoconazole, levoketoconazole, metyrapone, osilodrostat, pasireotide, cabergoline and mifepristone), and the way in which to monitor and treat them, based on retrospective studies and the most recently published prospective studies." | 2.82 | How best to monitor the specific side effects of medical treatments of Cushing's disease. ( Castinetti, F, 2022) |
| "Osilodrostat has been shown to be highly effective at maintaining normal urinary free cortisol in patients with CD." | 2.72 | Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide. ( Fleseriu, M; Han, AJ; Varlamov, EV, 2021) |
| "Medical therapy to control hypercortisolism in adrenal Cushing's syndrome is currently not the first-line therapy." | 2.66 | What is the role of medical therapy in adrenal-dependent Cushing's syndrome? ( Braun, LT; Reincke, M, 2020) |
| "Medical therapy for Cushing disease is primarily used to control hypercortisolism in patients whose disease persists or with recurrent disease after pituitary surgery, including those awaiting the salutary effects of radiation therapy." | 2.61 | Medical Management of Cushing Disease. ( Biller, BMK; Tritos, NA, 2019) |
| "Pasireotide was the only treatment to be assessed in a randomized trial and was supported by a 'moderate' level of evidence." | 2.50 | Efficacy of medical treatment in Cushing's disease: a systematic review. ( Gadelha, MR; Vieira Neto, L, 2014) |
| "Hypercortisolism induced by Cushing disease causes high morbidity and mortality." | 2.48 | New prospects for drug treatment in Cushing disease. ( Barahona Constanzo, MJ; del Pozo Picó, C, 2012) |
| "The goals of ideal medical therapy for Cushing's disease should be to target the aetiology of the disorder, and thus surgery is the current 'gold standard' treatment." | 2.46 | Medical therapy of Cushing's disease: where are we now? ( Alexandraki, KI; Grossman, AB, 2010) |
| "The most common cause of endogenous Cushing's disease in children older than 7 years is ACTH-dependent Cushing's disease (85%)." | 2.45 | [Cushing's syndrome: special issues]. ( Goñi Iriarte, MJ, 2009) |
| "Effective treatment of Cushing's disease can normalize biochemical levels, reverse comorbidities, and improve overall survival and quality of life." | 2.45 | Rationale for treatment and therapeutic options in Cushing's disease. ( Petersenn, S; Stewart, PM, 2009) |
| "Symptoms of hyperandrogenism are common in patients with Cushing's disease (CD), yet they are not sufficiently explained by androgen concentrations." | 1.72 | 11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing's disease. ( Adaway, JE; Auer, MK; Bidlingmaier, M; Braun, L; Hartmann, MF; Hawley, J; Keevil, B; Lottspeich, C; Nowotny, HF; Reincke, M; Reisch, N; Schilbach, K; Tschaidse, L; Vogel, F; Wudy, SA, 2022) |
| "Since hypercortisolism due to active Cushing's disease may worsen a COVID-19 infection, multi-disciplinary management that includes appropriate and prompt treatment strategies is mandatory in such cases." | 1.62 | Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. ( Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A, 2021) |
| "BLA = bilateral adrenalectomy CD = Cushing disease CS = Cushing syndrome eCRF = electronic case report form MRI = magnetic resonance imaging PCOS = polycystic ovary syndrome." | 1.46 | BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. ( Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS, 2017) |
| "A long-term recurrence rate of Cushing's disease ranging from 2%-25% has been reported." | 1.39 | [Predictors of long-term remission after transsphenoidal surgery in Cushing's disease]. ( Abellán Galiana, P; Escrivá, CM; Fajardo Montañana, C; Gómez Vela, J; Lillo, VR; Riesgo Suárez, PA, 2013) |
| "Imaging tests by CT/MRI identified the tumors in 8 of 16 (50%), in 4 of 11 (36%) and 4 of 6 (66." | 1.36 | Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. ( Doi, M; Hirata, Y; Izumiyama, H; Sugiyama, T; Yoshimoto, T, 2010) |
| "A diagnosis of preclinical Cushing's disease was made, and she was treated with 11-hydroxylase inhibitor metyrapone." | 1.34 | Preclinical Cushing's disease characterized by massive adrenal hyperplasia and hormonal changes after three years of metyrapone therapy. ( Nomura, K; Ohmori, K; Ohmori, N; Takano, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Emmerich, J | 1 |
| van Koppen, CJ | 1 |
| Burkhart, JL | 1 |
| Hu, Q | 1 |
| Siebenbürger, L | 1 |
| Boerger, C | 1 |
| Scheuer, C | 1 |
| Laschke, MW | 1 |
| Menger, MD | 1 |
| Hartmann, RW | 1 |
| Pivonello, R | 1 |
| Simeoli, C | 1 |
| Di Paola, N | 1 |
| Colao, A | 1 |
| Nowotny, HF | 1 |
| Braun, L | 1 |
| Vogel, F | 1 |
| Bidlingmaier, M | 1 |
| Reincke, M | 2 |
| Tschaidse, L | 1 |
| Auer, MK | 1 |
| Lottspeich, C | 1 |
| Wudy, SA | 1 |
| Hartmann, MF | 1 |
| Hawley, J | 1 |
| Adaway, JE | 1 |
| Keevil, B | 1 |
| Schilbach, K | 1 |
| Reisch, N | 1 |
| Castinetti, F | 3 |
| Tritos, NA | 1 |
| Biller, BMK | 2 |
| Braun, LT | 1 |
| Yuno, A | 1 |
| Kenmotsu, Y | 1 |
| Takahashi, Y | 1 |
| Nomoto, H | 1 |
| Kameda, H | 1 |
| Cho, KY | 1 |
| Nakamura, A | 1 |
| Yamashita, Y | 1 |
| Nakamura, J | 1 |
| Nakakubo, S | 1 |
| Kamada, K | 1 |
| Suzuki, M | 1 |
| Sugino, H | 1 |
| Inoshita, N | 1 |
| Konno, S | 1 |
| Miyoshi, H | 1 |
| Atsumi, T | 1 |
| Sawamura, Y | 1 |
| Shimatsu, A | 1 |
| Varlamov, EV | 1 |
| Han, AJ | 1 |
| Fleseriu, M | 1 |
| Geer, EB | 1 |
| Shafiq, I | 1 |
| Gordon, MB | 1 |
| Bonert, V | 1 |
| Ayala, A | 1 |
| Swerdloff, RS | 1 |
| Katznelson, L | 1 |
| Lalazar, Y | 1 |
| Manuylova, E | 1 |
| Pulaski-Liebert, KJ | 1 |
| Carmichael, JD | 1 |
| Hannoush, Z | 1 |
| Surampudi, V | 1 |
| Broder, MS | 1 |
| Cherepanov, D | 1 |
| Eagan, M | 1 |
| Lee, J | 1 |
| Said, Q | 1 |
| Neary, MP | 1 |
| van den Bosch, OF | 1 |
| Stades, AM | 1 |
| Zelissen, PM | 1 |
| Gadelha, MR | 1 |
| Vieira Neto, L | 1 |
| Goñi Iriarte, MJ | 1 |
| Alwani, RA | 1 |
| de Herder, WW | 1 |
| van Aken, MO | 1 |
| van den Berge, JH | 1 |
| Delwel, EJ | 1 |
| Dallenga, AH | 1 |
| De Jong, FH | 1 |
| Lamberts, SW | 1 |
| van der Lely, AJ | 1 |
| Feelders, RA | 1 |
| Stewart, PM | 1 |
| Petersenn, S | 1 |
| Alexandraki, KI | 1 |
| Grossman, AB | 1 |
| Doi, M | 1 |
| Sugiyama, T | 1 |
| Izumiyama, H | 1 |
| Yoshimoto, T | 1 |
| Hirata, Y | 1 |
| Barahona Constanzo, MJ | 1 |
| del Pozo Picó, C | 1 |
| Abellán Galiana, P | 1 |
| Fajardo Montañana, C | 1 |
| Riesgo Suárez, PA | 1 |
| Gómez Vela, J | 1 |
| Escrivá, CM | 1 |
| Lillo, VR | 1 |
| Liu, PY | 1 |
| Pincus, SM | 1 |
| Keenan, DM | 1 |
| Roelfsema, F | 1 |
| Veldhuis, JD | 1 |
| Miyoshi, T | 1 |
| Otsuka, F | 1 |
| Suzuki, J | 1 |
| Inagaki, K | 1 |
| Takeda, M | 1 |
| Kano, Y | 1 |
| Yamashita, T | 1 |
| Ogura, T | 1 |
| Date, I | 1 |
| Tanaka, Y | 1 |
| Hashimoto, K | 1 |
| Makino, H | 1 |
| Ohmori, N | 1 |
| Nomura, K | 1 |
| Ohmori, K | 1 |
| Takano, K | 1 |
| Obinata, D | 1 |
| Yamaguchi, K | 1 |
| Hirano, D | 1 |
| Yoshida, T | 1 |
| Soma, M | 1 |
| Takahashi, S | 1 |
10 reviews available for metyrapone and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Cushing's disease: adrenal steroidogenesis inhibitors.
Topics: Adrenocorticotropic Hormone; Cushing Syndrome; Female; Humans; Hypokalemia; Ketoconazole; Male; Mety | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Stud | 2022 |
Medical Management of Cushing Disease.
Topics: Cabergoline; Etomidate; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; S | 2019 |
What is the role of medical therapy in adrenal-dependent Cushing's syndrome?
Topics: Adrenal Gland Diseases; Cushing Syndrome; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH | 2020 |
Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Topics: Cushing Syndrome; Cytochrome P-450 CYP11B2; Enzyme Inhibitors; Etomidate; Humans; Hydrocortisone; Im | 2021 |
Efficacy of medical treatment in Cushing's disease: a systematic review.
Topics: Cabergoline; Ergolines; Female; Humans; Ketoconazole; Male; Metyrapone; Mitotane; Pituitary ACTH Hyp | 2014 |
[Cushing's syndrome: special issues].
Topics: Adolescent; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Hyperfunction; Adult; Child; Cush | 2009 |
Rationale for treatment and therapeutic options in Cushing's disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenalectomy; Choice Behavior; Combined Modality Therapy | 2009 |
Medical therapy of Cushing's disease: where are we now?
Topics: Dopamine Agonists; Humans; Hydrocortisone; Ketoconazole; Metyrapone; Mifepristone; Mitotane; Pituita | 2010 |
New prospects for drug treatment in Cushing disease.
Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trial | 2012 |
1 trial available for metyrapone and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Joint synchrony of reciprocal hormonal signaling in human paradigms of both ACTH excess and cortisol depletion.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Feedback; Female; Homeostasis; Humans; Hydroco | 2005 |
11 other studies available for metyrapone and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
Topics: Administration, Oral; Animals; Biological Availability; Chemistry Techniques, Synthetic; Cytochrome | 2017 |
11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing's disease.
Topics: Adrenocorticotropic Hormone; Androgens; Androstenedione; Androsterone; Cortisone; Dehydroepiandroste | 2022 |
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; C | 2021 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectom | 2017 |
Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Enzyme Inhibitors; Female; Humans; Hydrocortis | 2014 |
Biochemical predictors of outcome of pituitary surgery for Cushing's disease.
Topics: Adult; Corticotropin-Releasing Hormone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hy | 2010 |
Clinical features and management of ectopic ACTH syndrome at a single institute in Japan.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Aged; Corticotropin-Releasing Hormone; D | 2010 |
[Predictors of long-term remission after transsphenoidal surgery in Cushing's disease].
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenal Insufficiency; Adrenocorticotropic Ho | 2013 |
Periodic secretion of adrenocorticotropin in a patient with Cushing's disease manifested during pregnancy.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Female; Humans; Hydroc | 2005 |
Preclinical Cushing's disease characterized by massive adrenal hyperplasia and hormonal changes after three years of metyrapone therapy.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Glands; Adrenocorticotropic Hormone; Aged; Antime | 2007 |
Preoperative management of Cushing's syndrome with metyrapone for severe psychiatric disturbances.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Depressive Disorder; Female; Humans; Metyrapone; Mi | 2008 |